Check for updates

OPEN ACCESS

EDITED BY Daniela Adamo, University of Naples Federico II, Italy

REVIEWED BY Pia Lopez Lopez Jornet, University of Murcia, Spain Antonio Celentano, University of Melbourne, Australia

*CORRESPONDENCE Ioanina Părlătescu ⊠ ioanina.parlatescu@umfcd.ro

RECEIVED 28 February 2023 ACCEPTED 14 April 2023 PUBLISHED 15 May 2023

CITATION

Dugan C, Popescu BO, Ţovaru S, Părlătescu I, Musat IA, Dobre M, Ribigan AC and Milanesi E (2023) Neuropsychological assessment of Romanian burning mouth syndrome patients: stress, depression, sleep disturbance, and verbal fluency impairments. *Front. Psychol.* 14:1176147. doi: 10.3389/fpsyg.2023.1176147

COPYRIGHT

© 2023 Dugan, Popescu, Tovaru, Părlătescu, Musat, Dobre, Ribigan and Milanesi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Neuropsychological assessment of Romanian burning mouth syndrome patients: stress, depression, sleep disturbance, and verbal fluency impairments

Cosmin Dugan¹, Bogdan Ovidiu Popescu^{1,2,3}, Serban Țovaru⁴, Ioanina Părlătescu⁴*, Ioana Andreea Musat^{1,3}, Maria Dobre³, Athena Cristina Ribigan^{1,5} and Elena Milanesi^{1,3}

¹Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²Clinical Neurosciences, Geriatrics and Gerontology Departments, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Victor Babeş National Institute of Pathology, Bucharest, Romania, ⁴Department of Oral Pathology, Faculty of Dentistry, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Neurology Department, University Emergency Hospital, Bucharest, Romania

Burning Mouth Syndrome (BMS) is a chronic condition characterized by a burning sensation in the oral mucosa, lasting more than 2hours daily for more than 3months, without clinical and/or laboratory evidence. BMS is often comorbid with mood, and psychiatric disorders, and a complex pathophysiology and interaction between impairments in nociceptive processing and psychologic function is occurring. In this work, we aimed to define the neuropsychological profile specific for BMS patients for a better management of this complex disease. We conducted a case-control study comparing 120 BMS patients and 110 non-BMS individuals (CTRL). Sociodemographic data and lifestyle habits, were collected, along with data regarding quality of life (SF-36 scale), stress (PSS), depression and anxiety (MADRS and HADS scales), sleep quality (PSQI scale), and cognitive functions (MoCA, SVF and PVF tests). The statistical analysis revealed a lower general quality of life (p<0.001), worse sleep quality (p<0.001) in BMS patients than CTRL. The BMS patients also displayed a higher prevalence of mild depressive symptoms than CTRL applying the MADRS (p<0.001) and HADS-Depression scales (p=0.001), whereas no differences in anxiety symptoms were found between the two groups (p=0.174). Moreover, reduced scores semantic and phonemic verbal fluency tests (p<0.05) were found, but no change in cognition was observed through MoCA (p=0.551). Our results highlight that synergy between dentistry and neuropsychiatric assessment is essential for a successful management of BMS.

KEYWORDS

burning mouth syndrome, stress, depression, sleep disturbance, verbal fluency

Introduction

Burning mouth syndrome (BMS) is defined by the World Health Organization as a disease of the oral mucosa characterized by persistent chronic pain without clinical lesions and with normal biological investigations (World Health Organization, 2023). BMS is a complex, multifactorial, neuropathic chronic pain mainly described by the patients as a burning sensation

01

or pain (Adamo and Spagnuolo, 2022). The diagnostic criteria stated by the International Headache Society mention that the symptoms are present every day for more than 2 hours, last for more than 3 months, are usually bilateral, and have variable intensity (Headache Classification Committee of the International Headache Society (IHS), 2018). The oral mucosa has a normal clinical aspect. The main symptom features have a large heterogeneity, including "burn," "hot," "stinging," "tingling,"" itching," "intraoral foreign body sensation," "altered or unpleasant oral sensation," and associated symptoms represented by taste disturbances and dry mouth (Chmieliauskaite et al., 2021; Adamo and Spagnuolo, 2022).

A recent meta-analysis reported that the overall pooled prevalence of BMS is 1.73%, with a higher prevalence in females than males (1.15% vs. 0.38%) (Wu et al., 2021). Moreover, the prevalence seems to be increasing in post-menopausal women (Buchanan and Zakrzewska, 2008).

Based on the course of the symptoms, BMS is classified into three types: type 1- symptoms not presented on waking but arise and increase during the day; type 2- symptoms present all day from waking up; type 3- with symptoms in unusual oral sites and free days of symptoms (van der Waal, 2021).

Another classification, based on the concept that BMS is a neuropathic disorder, identifies two subtypes of this disease: a subgroup characterized by peripheral small diameter fiber neuropathy of the oral mucosa and a subgroup characterized by central neuropathy. In some patients, the presence of both subtypes may occur (Orliaguet and Misery, 2021; van der Waal, 2021).

Despite the fact that BMS is still considered an idiopathic pain disorder, in addition to oral symptoms, psychosocial distress is frequently reported by BMS patients.

The role of psychological factors in BMS has been the focus of several studies, which have shown that the quality of life may be significantly impacted by primary BMS (Pereira et al., 2021), with patients experiencing sleep disturbance (Chainani-Wu et al., 2011), stress (Jedel et al., 2020) depression and anxiety (Buljan et al., 2008; Davies et al., 2015; Sikora et al., 2018; Kim et al., 2020; Malta et al., 2021), and, in some cases, cognitive decline (Canfora et al., 2021).

Although no study could establish a direct causal relationship between BMS and sleep disturbances, several dimensions of sleep have been found altered in patients, including duration, sleep affecting daytime function, sleep quality, efficiency, and the ability to fall asleep (Alhendi et al., 2023). Likewise, the crosstalk between psychological symptoms—mostly depression and anxiety and BMS has not been explained either. However, it has been reported that treatment with different classes of antidepressants, benzodiazepines, as well as cognitive behavior therapy induces benefit in pain score reduction (Tan et al., 2022).

Because of the unclear multifactorial nature of this disorder, a clinical multidisciplinary approach to BMS patients that includes a detailed anamnesis, an oral clinical examination focused on the oral mucosa and any dental problems, a biological evaluation followed by neurological, cardiovascular, and psychiatric evaluations (Aravindhan et al., 2014; Adamo and Spagnuolo, 2022) is recommended.

However, determining the best BMS management strategy remains difficult (McMillan et al., 2016).

The current study's objectives were to examine the prevalence of stress, depressive and anxiety symptoms, sleep disturbances and cognitive impairments in a large cohort of BMS Romanian patients, compared to a control group of not affected individuals. Furthermore, this study also aimed at investigating, for the first time, the putative presence of semantic and phonemic verbal fluency impairment in BMS patients.

Materials and methods

A cohort of 120 patients with BMS and 110 non-BMS individuals (CTRL) were enrolled in this study at the Oral Medicine Department, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy. All the BMS patients diagnosed starting from 2017, were recalled for reevaluation in 2022, and those who provided written, informed consent were included in the study. The CTRL group was represented by dental patients (without any BMS symptoms) who were age- and sex-matched with the BMS group.

The study was approved by the scientific research ethics committee of Carol Davila" University (approval number 36988/2022), and all the participants provided written, informed consent. The BMS diagnosis was carried out in accordance with the recommendations of the WHO (World Health Organization, 2023) and the International Headache Society (Headache Classification Committee of the International Headache Society (IHS), 2018). The inclusion criteria for BMS patients were: (i) male or female, aged at least 18 years, (ii) oral symptoms present daily for more than 2h for at least 3 months, (iii) a normal clinical aspect of the oral mucosa, (iv) a negative oral fungal test, (v) biological tests (complete blood count, serum iron and ferritin, blood sugar levels, B1, B6, and B12 vitamins, as well as the thyroid panel) within a normal range, and (vi) no current psychiatric treatment. The CTRL group inclusion criteria were: (i) male or female, aged at least 18, (ii) absence of BMS symptoms and oral mucosal lesions, (iii) no record of psychiatric illness, and (iv) absence of debilitating medical conditions.

For each participant, the socio-demographic (age, sex, education, BMI, employment, marital status, and use of email, smartphones, and social networks), lifestyle, and habits (tobacco, alcohol, coffee, and fizzy drink consumption, as well as diet type and contact with animals) data were recorded. Each individual was screened by an expert neurologist using standardized questionnaires to assess quality of life with SF-36 scale (score range 0-100) (Ware and Sherbourne, 1992), stress with Perceived Stress Scale - PSS (score range 0-40; 0-13 = low stress, 14-26=moderate stress, 27-40=high stress) (Cohen et al., 1983), depression and anxiety symptoms with MADRS (score range 0-60; 0-6 = no depression, 7-19 = mild depression; 20-34 = moderatedepression, >35 = severe depression) (Williams and Kobak, 2008), and with HADS (score range 0-21; 0-7=normal, 8-10=mild; 11–14 = moderate, 15–21 = severe) (Zigmond and Snaith, 1983). The PSQI scale (score range 0-21; >5=significant sleep disturbance) (Carpenter and Andrykowski, 1998) was used to assess sleep quality. Furthermore, the individuals' self-reported the hours of night and day sleep durations. Cognitive functions with the MoCA (score range 0-30; <26 = cognitive impairment) (Nasreddine et al., 2005), semantic (SVF), and phonemic verbal fluency (PVF) tests were evaluated in elderly individuals (age > 60 years).

In the SVF the person was asked to list all of the animals he could think of in the next 60 s (cut off: score <17), and in the PVF test, the person was asked to name all of the words that begin with letter R in 60 s (cut off: score <17).

Statistical analysis was performed using IBM SPSS v25. All the variables were summed up with descriptive statistics like means, standard deviations, and frequencies. Differences between the groups were assessed using the Chi-squared test and the two-sample t-test for categorical and continuous variables, respectively. Correlations between continuous variables have been performed using Pearson's test.

Results

The groups of BMS patients and controls were not different in terms of age, sex, BMI, employment, marital status, and use of email, smartphone and social networks (p > 0.05), while a difference in education levels was observed, with BMS patients showing higher average years of schooling than controls (p < 0.001). Regarding lifestyle and habits, we found a higher frequency of consumers of coffee (p < 0.001), and fizzy drinks (p < 0.001) in the BMS group than in the CTRL. Moreover, the BMS patients reported being in more in contact with animals (pets or farm animals) than CTRL (p < 0.001) (Table 1).

When assessing the quality of life by the SF-36 scale, we observed that all individuals reported scores indicating from a good to excellent quality of life. However, the score in CTRL was significantly higher than those reported by the patients (p < 0.001). The PSS result showed higher levels of stress in BMS patients compared to controls, as well as a higher frequency of individuals with mild and moderate depression as shown by the MADRS (p < 0.001) and HADS-D (p = 0.001) tests. No difference in anxiety symptoms (HADS-A) was found between the two groups (p = 0.174). The analysis of the PSQI test revealed worse sleep quality in BMS patients (p < 0.001) than controls. Moreover, a different distribution of sleeping day and night hours was observed between the two groups (p < 0.001) (Table 2).

From the entire cohort, we then selected only elderly individuals aged above 60, obtaining the two following sub-groups homogeneous by age: 72 BMS (age mean 68.33 ± 5.84) and 59 CTRL (age mean 67.71 ± 5.04) (p = 0.621). These patients and controls underwent a cognitive screening with the MoCA, semantic (SVF), and phonemic verbal fluency (PVF) tests. The case–control analysis did not show any difference in the MoCA score, while a less performance of BMS patients was observed for both the SVF (p < 0.001) and PVF (p < 0.001) tests (Table 3).

We further correlated, in the BMS elderly patients, the scores of SVF and PVF with those obtained in the tests administered to assess stress, depression, anxiety, sleep quality, and cognitive functions. As expected, SVF and PVF negatively correlated with PSS (p=0.004, Pearson r=-0.338; p=0.004, Pearson r=-0.337, respectively), with HADS-D (p=0.01, Pearson r=-0.395; p=0.022, Pearson r=-0.269, respectively), and with PSQI (p<0.001, Pearson r=-0.486; p<0.001, Pearson r=-0.490, respectively). No further correlations were observed between verbal fluency and other parameters.

Discussion

BMS, a multifactorial condition mostly encountered in women, is a chronic painful disorder that affects the quality of life in most of the patients (Adamo et al., 2019; Pereira et al., 2021). Because its etiology is unclear, a line of research in the last decade has focused

TABLE 1 Socio-demographic data, lifestyle, and habits of CTRL and BMS
patients.

Socio-dem	ographic featu	res	
	CTRL (<i>N</i> =110)	BMS (<i>N</i> =120)	Significance
Age in years (mean±SD)	59.07±11.43	60.56 ± 11.71	* <i>p</i> = 0.332
Sex <i>N</i> (F%; M%)	82 (74.5%) F; 28 (25.5%) M	93 (77.5%) F; 27 (22.5%) M	$p^{*} = 0.600; \chi^{2} = 0.275$
Education in years (mean±SD)	13.82±1.04	15.00±1.74	[#] p<0.001
BMI (mean±SD)	26.84±3.13	26.70±3.47	* <i>p</i> = 0.751
Employment status N (%)	Unemployed = 3 (2.7%)	Unemployed = 3 (2.5%)	${}^{s}p = 0.970;$ $\chi^{2} = 0.537$
	Retired = 60 (54.5%)	Retired = 70 (58.3%)	
	Part-time job = 5 (4.5%)	Part-time job=6 (5%)	
	Full-time job = 31 (28.2%)	Full-time job = 29 (24.2%)	
	Own business = 11 (10%)	Own business = 12 (10%)	
Marital status N (%)	Single = 7 (6.4%) Married = 93 (84.5%)	Single = 5 (4.2%) Married = 99 (82.5%)	$p^{s} p = 0.687;$ $\chi^{2} = 1.478$
	Widow/er=7 (6.4%) Divorced=3 (2.7%)	Widow/er = 11 (9.1%) Divorced = 5 (4.2%)	
e-mail user N (%)	No user = 29 (26.4%) Basic user = 39 (35.4%) Advance user = 42 (38.2%)	No user = 37 (30.8%) Basic user = 41 (34.2%) Advance user = 42 (25%)	${}^{5}p = 0.746;$ $\chi^{2} = 0.586$
Smartphone user N (%)	No user = 2 (1.9%) Basic user = 48 (43.6%) Advance user = 60 (54.5%)	No user = 6 (5%) Basic user = 60 (50%) Advance user = 54 (45%)	${}^{8}p = 0.200;$ $\chi^{2} = 3.220$
Social Network users N (%)	No user = 54 (49.1%) Basic user = 22 (20%) Advance user = 34 (30.9%)	No user = 65 (54.2%) Basic user = 21 (17.5%) Advance user = 34 (28.3%)	${}^{8}p = 0.606;$ $\chi^{2} = 0.738$
Lifestyle and hab Tobacco consumers <i>N</i> (%)	bits Non-smoker = 71 (64.5%) Smoker = 39	Non-smoker = 81 (67.5%) Smoker = 39	$p^{s} p = 0.636;$ $\chi^{2} = 0.224$
	(35.5%)	(32.5%)	

(Continued)

TABLE 1 (Continued)

Socio-demographic features			
	CTRL (<i>N</i> =110)	BMS (<i>N</i> =120)	Significance
Alcohol consumers N (%)	No consumer = 61 (55.5%) Sporadic consumer = 43 (39.0%) Chronic moderate consumer = 6 (5.5%) Severe consumer = 0	No consumer = 81 (67.5%) Sporadic consumer = 35 (29.2%) Chronic moderate consumer = 3 (2.5%) Severe consumer = 1 (0.8%)	${}^{8}p = 0.157;$ $\chi^{2} = 5.212$
Coffee consumers N (%)	No consumer = 83 (75.5%) Sporadic consumer = 21 (19.1%) Chronic consumer (1 coffee/day) = 6 (5.4%) Chronic consumer (2-3 coffee/day) = 0	(0.8%) No consumer = 29 (24.2%) Sporadic consumer = 66 (55.0%) Chronic consumer (1 coffee/day) = 23 (19.2%) Chronic consumer (2–3 coffee/day) = 2 (1.6%)	${}^{s}p < 0.001;$ $\chi^{2} = 60.958$
Fizzy drinks consumers <i>N</i> (%)	No consumer = 97 (88.2%) Sporadic consumer = 12 (10.9%) Chronic consumer (2-31/ week) = 1 (0.9%)	No consumer = 73 (60.8%) Sporadic consumer = 41 (34.2%) Chronic consumer (2-31/ week) = 6 (5%)	$p^{s} < 0.001;$ $\chi^{2} = 22.435$
Contact with animals N (%)	No animals=94 (85.4%) Farm animals=7 (6.4%) Pets=9 (8.2%)	No animals = 66 (55%) Farm animals = 32 (26.7%) Pets = 22 (18.3%)	$p^{\circ} < 0.001;$ $\chi^2 = 25.992$

SD = standard deviation; *p-value was calculated with T-test; *p-value was calculated with Chi-square test. In bold are reported the significant results.

on psychological aspects, discovering significant associations between this medical condition and neuropsychological features. In this study, we evaluated a panel of socio-psychological and cognitive features in a large cohort of Romanian BMS patients and not affected individuals in order to identify specific characteristics associated with BMS.

Although the clinicians recommend to BMS patients to avoid acidic foods and liquids, such as tomatoes, orange juice, carbonated beverages, and coffee, analyzing the features related to lifestyle and habits, we observed a higher frequency of fizzy drink intake in BMS patients compared to controls. Moreover, BMS patients reported

TABLE 2 Quality of life, stress, depression, anxiety and sleep quality data	
of CTRL and BMS patients.	

Quality of life, stress, depression anxiety and sleep quality			
	CTRL (<i>N</i> =110)	BMS (<i>N</i> =120)	Significance
SF-36 total score (mean±SD) (min-max)	91.98±4.38 (77– 99)	86.10±5.46 (67– 95)	*p<0.001
PSS sum (mean±SD)	11.90±4.36	20.93±7.80	* <i>p</i> < 0.001
MADRS* N (%) *Available for 96 CTRL	No depression = 88 (91.7%) Mild depression = 8 (8.3%)	No depression = 72 (60%) Mild depression = 33 (27.5%) Moderate depression = 10 (8.3%) No depression, with treatment = 5 (4.2%)	$p^{s} < 0.001;$ $\chi^{2} = 29.542$
HADS-D N (%)	No depression = 109 (99%) Mild Depression = 1 (1%)	No depression = 105 (87.5%) Mild Depression = 15 (12.5%)	${}^{s}p = 0.001;$ $\chi^{2} = 11.913$
HADS-A N (%)	No Anxiety <8=110 (100%)	No Anxiety = 118 (98.3%) Mild Anxiety = 2 (0.7%)	${}^{s}p = 0.174; \chi^{2} = 1.849$
Global PSQI score (min- max)	6.90±4.04 (2-16)	9.62±3.76 (2–18)	*p<0.001
Sleeping night hours N (%)	$\leq 5 h = 0 (0\%)$ 5-6 h = 19 (17.3%) 6-7 h = 80 (72.7%) >7 h = 11 (10%)	$\leq 5 h = 5 (4.2\%)$ 5-6 h = 60 (50%) 6-7 h = 53 (44.1%) >7 h = 2 (1.7%)	$p^{s} p < 0.001;$ $\chi^{2} = 37.627$
Sleeping day hours (N (%))	No day sleep = 97 (88.2%) $\leq 1 h = 11 (10\%)$ 1-2 h = 2 (1.8%)	No day sleep = 72 (60%) $\leq 1 h = 46 (38.3\%)$ 1-2 h = 2 (1.7%)	$p^{s} > 0.001;$ $\chi^{2} = 24.802$

 $SD = standard \ deviation; \ {}^{s}p\ value \ was \ calculated \ with \ T-test; \ {}^{s}p\ value \ was \ calculated \ with \ Chi-square \ test. In \ bold \ are \ reported \ the \ significant \ results.$

spending more time with pets and farm animals than not affected individuals. Since it has been demonstrated that interaction with a pet can positively impact quality of life, happiness, and life satisfaction, as well as reduce depressive symptoms (Michalos, 2014), this outcome can represent a tentative way to improve their quality of life, which decreased in BMS patients as reported in our study.

10.3389/fpsyg.2023.1176147

TABLE 3 Cognitive and verbal characteristics of elderly (Age>60) CTRL and BMS patients.

Cognitive and verbal features			
	CTRL (<i>N</i> =59)	BMS (N =72)	Significance
MoCA	27.91 ± 1.92	27.69 ± 1.66	*p = 0.475
(mean±SD)	(23-30)	(23-30)	
(min-max)			
SVF	17.49 ± 1.78	15.46 ± 2.71	[#] p<0.001
(mean±SD)	(11-20)	(8-21)	
(min-max)			
PVF	16.02 ± 1.96	12.97 ± 2.65	[#] p<0.001
(mean±SD)	(10–19)	(6–19)	
(min-max)			

SD=standard deviation; *p-value was calculated with T-test; In bold are reported the significant results.

Our study also revealed higher levels of stress in patients than controls measured by the PSS, as reported also by Jedel and collaborators (Jedel et al., 2020) and by Nosratzehi et al. (2020), which, using the Holmes-Rahe questionnaire, found that patients with BMS had more stressful events than controls. Regarding anxiety and depression, in contrast with literature data (Malik et al., 2012; Malta et al., 2021), no anxiety symptoms were registered in the enrolled BMS patients. In our study, the presence of individuals with mild depressive symptoms, evaluated by two different scales, was more frequent in the BMS group than in the control group. The data on depression are in line with those reported in the literature. Indeed, many research groups reported higher levels of depression in BMS patients compared to controls measured by HADS (Malik et al., 2012; Lopez-Jornet et al., 2015; Leuci et al., 2022) and other instruments, including HAM-D (Nasreddine et al., 2005; Canfora et al., 2021, 2023) and the Beck Depression and Anxiety Inventory (BDI) (Buljan et al., 2008; Malta et al., 2021). In addition, in agreement with literature data (Chainani-Wu et al., 2011; Adamo et al., 2013; Lopez-Jornet et al., 2015; Adamo et al., 2018; Rezazadeh et al., 2021), our outcomes confirmed a higher frequency of poor sleep quality in BMS patients than controls. Overall, these findings are consistent with previous research suggesting that circadian rhythm dysfunction, which regulates pain perception, mood, and sleep, may be a clinically significant driver of this disease (Ritchie and Kramer, 2018).

When investigating the presence of signs of cognitive impairment in individuals aged over 60, the MoCA scale did not reveal any statistical difference between patients and controls. Even though the elderly BMS patients had a much higher education level than the controls, they did worse on tests of semantic and phonemic verbal fluency than the controls.

The evaluation of verbal fluency tasks is commonly used for assessing cognitive and linguistic abilities in both healthy and clinical populations (Pekkala, 2012; Thiele et al., 2016; Stielow and Stenneken, 2017; Turkstra, 2018). Both semantic and phonemic fluency evaluations have been used for studying functional brain metabolism in different psychiatric and neurological disorders, such as depression, schizophrenia, bipolar disorder, and other cognitivelinguistic impairments secondary to dementia or head trauma (Opasso et al., 2016; Yeung and Lin, 2021; Tassi et al., 2022). Moreover, verbal fluency scores have shown to be linked with cognitive impairment in mild and moderate Alzheimer's disease patients (Maseda et al., 2014). In our study, elderly BMS patients did not present general signs of cognitive impairment, according to the MoCA. However, dysfunctions in verbal fluency have been identified. When correlating the semantic and phonemic scores of elderly BMS patients with those obtained in the other neuropsychological tests we found that verbal tasks correlated with perceived stress, depression symptoms, and sleep quality, suggesting that this impairment can be a consequence of the general psychological distress that characterizes BMS patients. This result, to our knowledge, represents a new finding never reported in literature. Indeed, when analyzing the cognitive functions in BMS patients, Canfora et al. found a decline in attention, working memory, and executive functions, but not in praxis-constructive skills or verbal memory (Canfora et al., 2021).

Importantly, this is the first study that has examined verbal fluency in elderly BMS patients without cognitive impairment, finding a correlation between a deficit in verbal skills and BMS that is not related to cognitive decline, our patients being cognitively normal.

Moreover, to our knowledge, this is the largest study in terms of cohort size and number of evaluated features (lifestyle habits, data on quality of life, stress, depression, and anxiety, sleep quality, and cognitive functions) conducted on BMS patients from Eastern Europe.

The limitations of this study are represented by the lack of regression analysis and by the fact that the presence of comorbidities and the associated therapeutic regimen of the enrolled individuals have not been considered. Anyhow, the BMS diagnosis is based on the exclusion of other organic general and oral conditions causing oral pain, and one of the including criteria is the presence of biological tests within normal range.

In conclusion, our data, showing impairments related to quality of life, high levels of stress and depression, as well as sleeping disturbance and verbal fluency impairment, highlight that the BMS condition necessitates specific assistance with attention to psychological, psychiatric, and neurological issues. Taken together, these findings highlight the importance of a multidisciplinary approach to BMS, implying that collaboration between dentists, clinical psychologists, and psychiatrists is required for both diagnosis and treatment.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Scientific Research Ethics Committee of the "Carol Davila" University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

CD designed the study. BP and ST encouraged CD and supervised the project. CD and AR applied the neuropsychological tests. EM, MD, IM, AR, and IP analyzed the data. EM, MD, and IP wrote the manuscript with input from all authors. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by a grant from the Romanian Ministry of Research, Innovation and Digitization, CCCDI-UUEFISCDI, project number PN-III-P2-2.1-PED-2019-1339 within PNCDI III (contract number 564PED/2021) and 31PFE/30.12.2021.

References

Adamo, D., Pecoraro, G., Fortuna, G., Amato, M., Marenzi, G., Aria, M., et al. (2019). Assessment of oral health-related quality of life, measured by OHIP-14 and GOHAI, and psychological profiling in burning mouth syndrome: a case-control clinical study. *J. Oral Rehabil.* 47, 42–52. doi: 10.1111/joor.12864

Adamo, D., Sardella, A., Varoni, E., Lajolo, C., Biasotto, M., Ottaviani, G., et al. (2018). Giuliani, the association between burning mouth syndrome and sleep disturbance: a case-control multicentre study. *Oral Dis.* 24, 638–649. doi: 10.1111/ odi.12807

Adamo, D., Schiavone, V., Aria, M., Leuci, S., Ruoppo, E., Dell'Aversana, G., et al. (2013). Sleep disturbance in patients with burning mouth syndrome: a case-control study. *J. Orofac. Pain* 27, 304–313. doi: 10.11607/jop.1109

Adamo, D., and Spagnuolo, G. (2022). Burning mouth syndrome: an overview and future perspectives. *Int. J. Environ. Res. Public Health* 20:682. doi: 10.3390/ ijerph20010682

Alhendi, F., Eugene, K., Laurel, G., and Patricia, C. (2023). The association of sleep disturbances with burning mouth syndrome: an overlooked relationship—a qualitative systematic review. *Oral Dis.* 29, 6–20. doi: 10.1111/odi.14051

Aravindhan, R., Vidyalakshmi, S., Muniapillai Siva Kumar, C. C., Ali Balasubramanium, S. A., and Prasad, V. S. (2014). Burning mouth syndrome: a review on its diagnostic and therapeutic approach. *J. Pharm. Bioallied Sci.* 6, 21–S25. doi: 10.4103/0975-7406.137255

Buchanan, J., and Zakrzewska, J. (2008). Burning mouth syndrome. BMJ Clin. Evid. 2016:1301.

Buljan, D., Savić, I., and Karlović, D. (2008). Correlation between anxiety, depression, and burning mouth syndrome. *Acta Clin. Croat.* 47, 211–216.

Canfora, F., Calabria, E., Cuocolo, R., Ugga, L., Buono, G., Marenzi, G., et al. (2021). Burning fog: cognitive impairment in burning mouth syndrome. *Front. Aging Neurosci.* 13:727417. doi: 10.3389/fnagi.2021.727417

Canfora, F., Calabria, E., Pecoraro, G., Leuci, S., Coppola, N., Mazzaccara, C., et al. (2023). Prevalence of hypertension and correlation with mental health in women with burning mouth syndrome: a case-control study. *Front. Cardiovasc. Med.* 9:969148. doi: 10.3389/fcvm.2022.969148

Carpenter, J. S., and Andrykowski, M. A. (1998). Psychometric evaluation of the Pittsburgh sleep quality index. J. Psychosom. Res. 45, 5-13. doi: 10.1016/s0022-3999(97)00298-5

Chainani-Wu, N., Madden, E., and Silverman, S. (2011). A case-control study of burning mouth syndrome and sleep dysfunction. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 112, 203–208. doi: 10.1016/j.tripleo.2011.03.014

Chmieliauskaite, M., Stelson, E. A., Epstein, J. B., Klasser, G. D., Farag, A., Carey, B., et al. (2021). Consensus agreement to rename burning mouth syndrome and improve ICD-11 disease criteria: an international Delphi study. *Pain* 162, 2548–2557. doi: 10.1097/j.pain.0000000002243

Cohen, S., Kamarck, T., and Mermelstein, R. (1983). A global measure of perceived stress. J. Health Soc. Behav. 24, 385–396. doi: 10.2307/2136404

Davies, S. J., Underhill, H. C., Abdel-Karim, A., Christmas, D. M., Bolea-Alamanac, B. M., Potokar, J., et al. (2015). Different oral symptoms of burning mouth syndrome may be linked to depression and anxiety in different ways. *Acta Odontol. Scand.* 74, 155–160. doi: 10.3109/00016357.2015.1100324

Headache Classification Committee of the International Headache Society (IHS) (2018). The international classification of headache disorders, 3rd edition. *Cephalalgia* 38, 1–211. doi: 10.1177/0333102417738202

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Jedel, E., Elfström, M. L., and Hägglin, C. (2020). Differences in personality, perceived stress and physical activity in women with burning mouth syndrome compared to controls. *Scand. J. Pain* 21, 183–190. doi: 10.1515/sjpain-2020-0110

Kim, J.-Y., Kim, Y. S., Ko, I., and Kim, D.-K. (2020). Association between burning mouth syndrome and the development of depression, anxiety, dementia, and Parkinson disease. *JAMA Otolaryngol. Head Neck Surg.* 146, 561–569. doi: 10.1001/jamaoto.2020.0526

Leuci, S., Coppola, N., Adamo, D., Crocetto, F., Barone, B., Baldares, S., et al. (2022). Sexual desire, mood disorders and sleep disturbances in female BMS patients: a controlled study. *J. Oral Pathol. Med.* 52, 276–282. doi: 10.1111/jop.13362

Lopez-Jornet, P., Lucero-Berdugo, M., Castillo-Felipe, C., Zamora Lavella, C., Ferrandez-Pujante, A., and Pons-Fuster, A. (2015). Assessment of self-reported sleep disturbance and psychological status in patients with burning mouth syndrome. *J. Eur. Acad. Dermatol. Venereol.* 29, 1285–1290. doi: 10.1111/jdv.12795

Malik, R., Misra, D., Misra, A., Panjwani, S., and Goel, S. (2012). Assessment of anxiety and depression in patients with burning mouth syndrome: a clinical trial. *J. Midlife Health* 3, 36–39. doi: 10.4103/0976-7800.98816

Malta, C. E., Nóbrega, C. F., Gurgel, W., Costa, D. C., Matos, C. A. C. A., Bitu, S. F., et al. (2021). Association of anxiety, depression, and stress with burning mouth syndrome: a case-control study. *Gen. Dent.* 69, 46–52.

Maseda, A., Lodeiro-Fernández, L., Lorenzo-López, L., Núñez-Naveira, L., Balo, A., and Millán-Calenti, J. C. (2014). Verbal fluency, naming and verbal comprehension: three aspects of language as predictors of cognitive impairment. *Aging Ment. Health* 18, 1037–1045. doi: 10.1080/13607863.2014.908457

McMillan, R., Forssell, H., Buchanan, J. A. G., Glenny, A.-M., Weldon, J. C., and Zakrzewska, J. M. (2016). Interventions for treating burning mouth syndrome. *Cochrane Database Syst. Rev.* 18:CD002779. doi: 10.1002/14651858.cd002779.pub3

Michalos, A. C. ed., (2014). Encyclopedia of Quality of Life and Well-Being Research. Springer: Berlin.

Nasreddine, Z. S., Phillips, N. A., Bedirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005). The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* 53, 695–699. doi: 10.1111/j.1532-5415.2005.53221.x

Nosratzehi, T., Payandeh, A., and DehYadegari, F. (2020). The complaints, type, and severity of stressful events in patients with burning mouth syndrome referring to Zahedan School of Dentistry. *Clin. Cosmet. Investig. Dent.* 12, 123–130. doi: 10.2147/ccide.s229910

Opasso, P. R., Barreto, S. D. S., and Ortiz, K. Z. (2016). Phonemic verbal fluency task in adults with high-level literacy. *Einstein (São Paulo)* 14, 398–402. doi: 10.1590/ s1679-45082016ao3629

Orliaguet, M., and Misery, L. (2021). Neuropathic and psychogenic components of burning mouth syndrome: a systematic review. *Biomol. Ther.* 11:1237. doi: 10.3390/biom11081237

Pekkala, S. (2012). "Verbal fluency tasks and the neuropsychology of language" in *The Handbook of the Neuropsychology of Language*. ed. M. Faust (Chichester, UK: Wiley-Blackwell), 619–634.

Pereira, J. V., Normando, A. G., Rodrigues-Fernandes, C. I., Rivera, C., Santos-Silva, A. R., and Lopes, M. A. (2021). The impact on quality of life in patients with burning mouth syndrome: a systematic review and Meta-analysis. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* 131, 186–194. doi: 10.1016/j. 0000.2020.11.019

Rezazadeh, F., Farahmand, F., Hosseinpour, H., Shahriarirad, R., and Sabet Eghlidi, A. (2021). The association between emotional stress, sleep disturbance, depression, and burning mouth syndrome. *Biomed. Res. Int.* 2021, 1–6. doi: 10.1155/2021/5555316

Ritchie, A., and Kramer, J. M. (2018). Recent advances in the etiology and treatment of burning mouth syndrome. J. Dent. Res. 97, 1193–1199. doi: 10.1177/0022034518782462

Sikora, M., Verzak, Z., Matijevic, M., Vcev, A., Siber, S., Music, L., et al. (2018). Anxiety and depression scores in patients with burning mouth syndrome. *Psychiatr. Danub.* 30, 466–470. doi: 10.24869/psyd.2018.466

Stielow, A., and Stenneken, P. (2017). Der Beitrag exekutiver und sprachlicher Teilleistungen in semantischen und formal-lexikalischen Wortflüssigkeitsaufgaben. *Sprache. Stimme. Gehör.* 41, 197–203. doi: 10.1055/s-0043-117202

Tan, H. L., Smith Jared, G., Jan, H., and Tara, R. (2022). A systematic review of treatment for patients with burning mouth syndrome. *Cephalalgia* 42, 128–161. doi: 10.1177/03331024211036152

Tassi, E., Boscutti, A., Mandolini, G. M., Moltrasio, C., Delvecchio, G., and Brambilla, P. (2022). A scoping review of near infrared spectroscopy studies employing a verbal fluency task in bipolar disorder. *J. Affect. Disord.* 298, 604–617. doi: 10.1016/j. jad.2021.11.019

Thiele, K., Quinting, J. M., and Stenneken, P. (2016). New ways to analyze word generation performance in brain injury: a systematic review and meta-analysis of additional performance measures. *J. Clin. Exp. Neuropsychol.* 38, 764–781. doi: 10.1080/13803395.2016.1163327

Turkstra, L. S. (2018). "Verbal fluency" in *Encyclopedia of Clinical Neuropsychology*. eds. J. Kreutzer, J. DeLuca and B. Caplan (Cham: Springer), 3576–3579.

van der Waal, Isaäc. Burning Mouth Disease: A Guide to Diagnosis and Management. Cham, Switzerland: Springer, (2021).

Ware, J. E., and Sherbourne, C. D. (1992). The MOS 36-Item short-form health survey (SF-36). *Med. Care* 30, 473–483. doi: 10.1097/00005650-199206000-00002

Williams, J. B. W., and Kobak, K. A. (2008). Development and reliability of a structured interview guide for the Montgomery-Åsberg depression rating scale (SIGMA). *Br. J. Psychiatry* 192, 52–58. doi: 10.1192/bjp.bp.106.032532

 $\label{eq:world} World Health Organization (2023). DA0E0 burning mouth syndrome. ICD-11 for Mortality and Morbidity Statistics. Available at: https://icd.who.int/browsel1/l-m/en#/ http://id.who.int/icd/entity/618998878$

Wu, S., Zhang, W., Yan, J., Noma, N., Young, A., and Yan, Z. (2021). Worldwide prevalence estimates of burning mouth syndrome: a systematic review and Metaanalysis. *Oral Dis.* 28, 1431–1440. doi: 10.1111/odi.13868

Yeung, M. K., and Lin, J. (2021). Probing depression, schizophrenia, and other psychiatric disorders using fNIRS and the verbal fluency test: a systematic review and meta-analysis. *J. Psychiatr. Res.* 140, 416–435. doi: 10.1016/j. jpsychires.2021.06.015

Zigmond, A. S., and Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x